IMPACT OF THE BIOLOGICAL RATIO ON MEDICAL DECISION MAKING IN WOMEN SUSPECTED OF PREECLAMPSIA
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Jan 24, 2024
Trial Information
Current as of July 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • pregnant patients over 24 weeks of amenorrhea
- • aged 18 and over
- • with suspicion of preeclampsia defined by the appearance of pregnancy-induced hypertension (≥ 140 in systolic and/or 90 mmHg in diastolic pressure over 2 measurements at 4 hours intervals) OR proteinuria (≥ 0.3 g per 24 hours).
- • who systematically gave oral consent after submitting the information sheet
- Exclusion Criteria:
- • pregnant women with both hypertension and proteinuria because they already have a confirmed diagnosis of preeclampsia.
- • receiving antihypertensive treatment before pregnancy
- • or refusing to participate in the study The sFlt-1/PlGF ratio was measured only when clinically indicated as per the investigator's judgment.
About Centre Hospitalier Universitaire De Saint Etienne
The Centre Hospitalier Universitaire (CHU) de Saint-Étienne is a leading academic medical center in France, dedicated to advancing healthcare through innovative clinical research and high-quality patient care. With a robust infrastructure that supports a wide range of medical specialties, CHU de Saint-Étienne fosters collaboration between healthcare professionals, researchers, and academic institutions. The center is committed to conducting rigorous clinical trials that adhere to ethical standards and regulatory requirements, aiming to improve treatment outcomes and enhance the overall health of the community. Through its dedication to scientific excellence and patient-centered care, CHU de Saint-Étienne plays a pivotal role in the advancement of medical knowledge and the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint étienne, , France
Patients applied
Trial Officials
BARJAT Tiphaine, MD
Principal Investigator
CHU DE SAINT-ETIENNE
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported